Search Results - "S. V. MISHUGIN"

The castration level of testosterone and hormonal resistance of prostate cancer in androgen deprivation therapy by Rusakov, I. G., Gritskevich, A. A., Baitman, T. P., Mishugin, S. V.

“…This review is dedicated to the impact of modern achievements on the definition and diagnostics of castration-resistant prostate cancer (PCa) (CRPC),…”
Get full text

Еfficiacy and safety of radium-223 in the treatment of metastatic castration-resistant prostate cancer by Rusakov, I. G., Gritskevich, A. A., Baitman, T. P., Mishugin, S. V.

“…Bone metastases often develop in patients with prostate cancer (PC) as a natural stage in the course of the disease. The skeletal system is the most typical…”
Get full text

Second line therapy for metastatic urothelial carcinoma. Clinical case of vinflunine use by Gritskevich, A. A., Popov, A. Yu, Rusakov, I. G., Vozniy, E. K., Makarov, V. A., Gridnev, D. I., Baitman, T. P., Mishugin, S. V., Novikova, I. V., Khromova, S. V.

“…Urothelial cancer occupies a significant place in the routine practice of cancer treatment. Systemic antitumor treatment of patients with metastatic urothelial…”
Get full text

The role of sunitinib in the therapy of metastatic renal cell carcinoma by Rusakov, I. G., Gritskevich, A. A., Baitman, T. P., Shipilova, A. N., Mishugin, S. V.

“…The standards of treatment for metastatic renal cell carcinoma (mRCC) have changed significantly from unsuccessful attempts of radiation and cytostatic therapy…”
Get full text

Study of the economic efficiency of the combined method of Octreotide-depo + dexamethasone therapy in the treatment of patients with castration-resistant prostate cancer by Mishugin, S. V., Rusakov, I. G., Novikova, I. V., Gritskevich, A. A.

“…Prostate cancer (PC) is one of the major health problems of the male population. The most difficult is the treatment of metastatic castration-resistant…”
Get full text

POSSIBILITIES OF RADIUM-223 APPLICATION IN THERAPY OF PROSTATE GLAND CANCER by A. A. GRITSKEVICH, S. V. MISHUGIN, I. G. RUSAKOV

“…In recent years several therapeutic options have been developed that significantly improve the survival of patients with metastatic treatment-resistant…”
Get full text

THE PLACE OF ENZALUTAMIDE IN THE SERIAL TREATMENT OF TREATMENT-RESISTANT PROSTATE CANCER by A. A. GRITSKEVICH, S. V. MISHUGIN, I. G. RUSAKOV

“…Prostate cancer initially responds to androgen-deprivation therapy, but most patients eventually develop a castration-resistant form of disease. Enzalutamid is…”
Get full text

POSSIBILITIES OF A COMBINATION OF DOCETAXEL WITH ANDROGEN DEPRIVATION IN INITIAL THERAPY OF HORMONESENSITIVE PROSTATE CANCER by A. A. GRITSKEVICH, S. V. MISHUGIN, I. G. RUSAKOV

“…Androgen deprivation therapy (ADT) is used in the treatment of prostate cancer metastatic cancer (PC) since the first description of its hormone dependence in…”
Get full text

EVALUATION OF EFFECT OF PROLONGED ACTION SOMATOSTATIN ANALOGUE – OCREOTIDE-DEPO – ON THE FOLLOWING HORMONAL AND CYTOTOXIC THERAPY IN PATIENTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (М-CRPC) by Mishugin, S. V., Gritskevich, A. A., Mordovin, A. A., Rusakov, I. G.

“…Therapy of CRPC is one of the most difficult problems in oncourology. Until now the optimal consequence of use of drugs in CRPC is not determined. Study…”
Get full text

DEVELOPMENT AND CLINICAL EFFECTIVENESS OF ANTIANDROGENS IN THE TREATMENT OF ADVANCED PROSTATE CANCER by S. V. MISHUGIN, A. A. GRITSKEVICH, I. G. RUSAKOV

“…Prostate cancer (PCa) is a hormonsensitive tumor. Due to the discovery of the androgen receptor (AR) it became possible to implement the antiandrogens as drugs…”
Get full text

CLINICAL ASSESSMENT OF TAXANES IN THE FIRST-LINE CYTOTOXIC THERAPY OF CASTRATION-RESISTANT PROSTATE CANCER by A. A. GRITSKEVICH, S. V. MISHUGIN, A. A. TEPLOV, I. G. RUSAKOV

“…The article tells about the current problems in the treatment of castrate-resistant prostate cancer. An extensive search for more effective treatments resulted…”
Get full text

EVALUATION OF EFFICACY OF BUSERELIN-DEPO IN PATIENTS WITH LOCALLY ADVANCED AND METHASTATIC PROSTATE CANCER by S. V. MISHUGIN, A. A. DROBYAZKO, A. A. MORDOVIN, A. A. GRICKEVICH, I. G. RUSAKOV

“…Our surveillance was performed for 358 patients with locally advanced and disseminated prostate gland cancer who were treated by analogues of LHRH. Patients in…”
Get full text

Cytotoxic therapy for prostate cancer by I. G. Rusakov, S. V. Mishugin

“…Интервью с вице-президентом Российского общества онкоурологов (РООУ), врачом-онкологом Московской городской клинической больницы № 57, доктором медицинских…”
Get full text

The new approaches to the treatment of castration- resistant prostate cancer: PARP inhibitors by А. А. Gritskevich, I. G. Rusakov, Т. Р. Baitman, S. V. Mishugin

“…Prostate cancer (PC) is one of the leading causes of cancer death in the male population. Currently, the pathogenesis of prostate cancer has been studied in…”
Get full text

Immune checkpoint inhibitors in bladder cancer therapy: the experience with avelumab by Gritskevich, A. A., Baitman, T. P., Mishugin, S. V., Popov, A. Yu, Yagudaev, D. M., Falaleeva, L. A., Rusakov, I. G.

“…Immune checkpoint inhibitors have revolutionized the treatment of urothelial carcinoma. They are now part of the standard of care for locally advanced or…”
Get full text

Atezolizumab (Tecentriq) as first-line therapy in patients with metastatic urothelial carcinoma by Gritskevich, A. A., Baitman, T. P., Mishugin, S. V., Popov, A. Yu, Oganyan, V. A., Rusakov, I. G., Kostin, A. A.

“…Introduction . Nowadays the standard of care for locally advanced and metastatic urothelial carcinoma (UC) is a combination of platinum-based drugs. However,…”
Get full text

THE PROGNOSTIC VALUE OF BASELINE PSA BLOOD IN THE TREATMENT OF PROSTATE CANCER by A. A. Gritskevich, V. L. Medvedev, S. V. Mishugin, N. A. Apolskaya, I. G. Rusakov

“…The role of the level of prostate specific antigen ( PSA) before initial therapy discusses widely as a prognostic factor in the  treatment of prostate cancer …”
Get full text

TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER by T. N. Skvortsova, S. V. Mishugin, A. A. Gritskevich, I. G. Rusakov

“…Currently, the study of mechanisms of development and introduction of the most effective treatment for castration-resistant prostate cancer (CRPC) – one of the…”
Get full text

Effective suppression of testosterone: the best castration therapy for hormone-sensitive prostate cancer? by A. A. Gritskevich, S. V. Mishugin, A. A. Teplov, V. L. Medvedev, I. G. Rusakov

“…Androgen suppression strategy has become the key treatment of advanced prostate cancer. Historically, testosterone level below 1.73 nmol/l (50 ng/dl) was…”
Get full text

The role of prostate-specific antigen in the prediction of hormone-sensitive prostate cancer by A. A. Gritskevich, S. V. Mishugin, A. A. Teplov, V. L. Medvedev, I. G. Rusakov

“…429 patients with histologically confirmed prostate cancer undergoing various treatment from 1995 till 2014 were studied retrospectively. Overall survival with…”
Get full text